ArticleJournal of Korean medical science2025
Long-Term Clinical Outcomes of ABO-Incompatible Kidney Transplantation in Patients With High Baseline Anti-A/B Antibody Titers.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Challenge to Opportunity: ABO-Incompatible Kidney Transplantation to Expand the Donor Pool at a Single Center.Cureus · 2026Article
- Serum Creatinine Level at One Month Post-Transplant Predicts 3-Year and 5-Year Graft Survival and Renal Function: A Large Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aimed to investigate the long-term clinical outcomes of ABO-incompatible kidney transplantation (ABO icKT) in patients with high baseline anti-A/B antibody titers.
methodsThis study included 271 cases of ABO icKT. Of these, 42 patients with a baseline antibody titer of ≥ 1:256 were assigned to the high-titer group, while the remaining 229 patients were categorized into the low-titer group. We compared the groups regarding the number of required pre-transplant plasmapheresis (PP) and intravenous immunoglobulin (IVIG) sessions. Clinical outcomes included post-operative bleeding, biopsy-proven acute rejection (BPAR), infectious complications, changes in allograft function, and long-term allograft and patient survival.
resultsThe high-titer group required significantly more sessions of PP and IVIG than the low-titer group (8.74 ± 2.68 vs. 3.85 ± 1.64;
conclusionPatients with high baseline anti-A/B titers demonstrated comparable short-term and long-term patient and allograft outcomes to those in the low-titer group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.